August 07, 2026

Combating the pandemic: Diagnostic chips ten times more sensitive

Combating the pandemic: Diagnostic chips ten times more sensitive


A team at KIT has developed a solution that significantly improves novel biosensors for medical use and enables faster diagnosis of infectious diseases

Hände mit blauen Schutzhandschuhen halten eine Multiwell-Platte in einem Labor.
Assays sind in der Labormedizin Testsysteme zum Nachweis bestimmter Substanzen. Forschende des KIT haben nun um ein Vielfaches sensiblere Platten entwickelt.

Rapid, straightforward and, at the same time, accurate diagnosis of highly contagious pathogens such as the SARS-CoV-2 virus, which caused the coronavirus pandemic, is crucial to curbing the spread of disease. This helps to minimise not only deaths but also economic damage. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a solution that makes medical diagnostic plates, known as assays, significantly more sensitive.

Nanoparticles improve electron transfer

The team led by Professor Pavel Levkin from the Institute for Biological and Chemical Systems (IBCS) at KIT is using innovative assays based on electrochemiluminescence. In this process, the transfer of electrons excites electrochemical elements on a surface, causing them to glow. In medical samples, the light indicates the presence of a pathogen. The brighter the light, the more pathogens are present in the sample.

The researchers increased the sensitivity of the assays tenfold by coating gold electrodes with silicon dioxide nanoparticles. This improved electron transfer and, consequently, the intensity of the light signal. The scientists were thus able to detect the SARS-CoV-2 virus in samples much more quickly and accurately.

Furthermore, the team optimised the surface of the assays for multiple applications, enabling several measurements to be carried out on a single sample. According to the researchers, it should even be possible in future to detect several pathogens simultaneously in the same sample. “Our platform can advance multiplex diagnostics for the rapid detection of pathogens and find broader applications in public health,” explain Yuliang Shao and Tatiana Starikova from the IBCS, who played a leading role in the development.

Our latest News

discover more
Combating the pandemic: Diagnostic chips ten times more sensitive

Combating the pandemic: Diagnostic chips ten times more sensitive

A team at KIT has developed a solution that significantly improves novel biosensors for medical use and enables faster diagnosis of infectious diseases Rapid, straightforward and, at the same time, accurate diagnosis of highly contagious pathogens such as the SARS-CoV-2 virus, which caused the coronavirus pandemic, is crucial to curbing the spread of disease. This […]

Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp